Aave plans RWA Hub on Avalanche with USA₮ support
Aave plans to launch a dedicated real world asset credit market on Avalanche through its upcoming Aave V4 RWA Hub, allowing institutions to borrow against tokenized assets without selling their underlying positions.
The RWA Hub will launch with support for USA₮, Tether’s dollar backed stablecoin issued by Anchorage Digital Bank, giving institutions access to onchain dollar liquidity while using tokenized assets as collateral.
Built on Aave V4’s existing Avalanche deployment, the market will use Aave’s Hub and Spoke architecture to create specialized credit markets with their own collateral rules and risk parameters while remaining connected to Aave’s broader liquidity network.
Aave said the structure could support tokenized Treasuries, money market funds, private credit, real estate and corporate bonds.
The launch comes as the tokenized real world asset market has grown about 40% this year to more than $51 billion. Avalanche currently hosts more than $3.4 billion in tokenized assets.
The crypto and markets news you actually need—every morning.
Daily. Free. Join 34,000+ readers across crypto, finance, and policy.
We respect your privacy. Unsubscribe anytime.
Aave founder Stani Kulechov said the new market is intended to move tokenized assets beyond issuance and allow institutions to use them directly as collateral in credit markets.
USA₮ will serve as the initial borrowing asset, providing institutions with a federally regulated digital dollar option for borrowing and settlement.
Aave said the RWA Hub will also allow individual markets to isolate risk while still drawing from shared liquidity, helping institutions access capital without having to sell tokenized holdings.
The launch extends Aave’s existing presence on Avalanche and forms part of the broader rollout of Aave V4, which is designed to support specialized lending markets for different asset classes.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
University of Michigan October Consumer Sentiment Index falls to a five-month low, with the Current Economic Conditions Indicator hitting a historic low
The University of Michigan’s Consumer Sentiment Index for October dropped to 46.3, below the market expectation of 47.6. The component reflecting current economic conditions decreased to 44.7, setting a new historical low, while the expectations component edged up to 47.3, marking its first rebound since July. Consumers’ one-year inflation expectations rose to 4.7%, and five-to-ten-year inflation expectations increased to 3.5%. According to the survey director, consumers from different political parties agree that the economic outlook has weakened compared to the beginning of the year.
WTI holds steady as traders weigh US-Iran tensions and supply risks
Japan: Bond outflows reshape global yields - Commerzbank
BUZZ - JPMorgan gives “overweight” rating to LSD-based therapies, Definium stock rises
Latest Updates, October 9th - ** Definium Therapeutics (DFTX.O) shares rose 7.4% to $36.7 ** If the rally holds, the stock is set for its biggest single-day gain since June ** JPMorgan initiated coverage of the stock with an "Overweight" rating and a target price of $84 ** The bank stated that Definium’s lead candidate drug, DT120 ODT, has the potential to transform the treatment landscape for neuropsychiatric disorders ** Based on current data, the institution considers DT120 ODT (an LSD oral formulation for the treatment of major depressive disorder and generalized anxiety disorder) to be a "de-risked asset" ** The new target price implies a 145.7% upside from the latest closing price ** "While changes in the macro environment may present potential investment risks to the sector, we believe the positives for Definium outweigh the negatives," the bank stated ** A period of "frequent landmark events" is expected ahead, including plans to submit a new drug application to the FDA in the first half of 2027 ** The bank projects that total sales of DT120 orally disintegrating tablets (ODT) will approach $5 billion by 2035 ** Including intraday volatility, the stock has more than doubled in value year-to-date (For the convenience of non-English speakers, Reuters has automated this report’s translation into several other languages. Due to possible errors in automated translation or lack of full context, Reuters does not guarantee the accuracy of the automated translation and provides it solely as a convenience to readers. Reuters accepts no liability for any damage or loss arising from the use of automated translation.)
Crypto prices
More
